Nurotron Biotechnology Exhibits in Havana

Share Article

Medical device company presents cochlear implant system at Pan-American Congress

Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, will participate in the Pan-American Congress of Otorhinolaryngology and Head and Neck Surgery, taking place June 13-16 in Havana.

The event will mark Nurotron’s first exhibition at the Congress. The company, based in China, has been accelerating its presence in the Americas to address growing market interest in its products, according to Chu Li, CEO. Nurotron also exhibited at the International Conference on Cochlear Implants (CI 2016) in Toronto last month, and at the Iberoamerican Conference on Cochlear Implants and Related Sciences in Sao Paulo, Brazil, in 2015.

In Havana, Nurotron will exhibit its Venus Cochlear Implant System, an effective solution for children and adults suffering from severe and profound hearing loss. Executives also will discuss plans for the market introduction of the company’s Enduro speech processor, featuring the Nurotron C-Tone™ strategy to improve tonal recognition and increase comprehension. Nurotron will participate in a manufacturer’s symposium, as well as present results of its Neural Response Measurement (NRM) telemetry program.

The Pan American Congress offers a timely opportunity to maintaim the momentum Nurotron experienced in Toronto, says Li. “Surgeons around the world are viewing Nurotron as a change agent in the industry, bringing a high-quality, reliable alternative to the market.” He adds that the interest from U.S. and Canadian surgeons has been particularly impressive since they know that Nurotron’s product will not be available in those countries for two-three years because of regulatory processes.

The Pan-America Congress will meet in Havana in June for the first time since 1952. The meeting will feature lectures, roundtable discussions and poster presentations.

Nurotron Biotechnology Co., Ltd. (
Nurotron Biotechnology is a medical device company that designs, develops and markets neurostimulation systems. The company’s flagship system is the Venus Cochlear Implant System, a safe, reliable and effective solution for children and adults suffering from severe and profound hearing loss. Nurotron’s patent portfolio also includes an auditory brainstem implant, artificial retina system, and systems to treat paralysis due to stroke.

Founded in 2006, Nurotron maintains its research and development center in Irvine, Calif., and manufacturing facilities in Hangzhou, China.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Aimee Bennett

Rick Giancola